ARTICLE | Company News
Editas names Bosley CEO
June 25, 2014 12:24 AM UTC
Genome editing company Editas Medicine (Cambridge, Mass.) hired Katrine Bosley as CEO. She was CEO of Avila Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired in 2012. Bosley succeeds Kevin Bitterman, a partner at Editas investor Polaris Partners who was serving as interim president. Editas secured $43 million in a tranched series A round last year from Polaris; Flagship Ventures; and Third Rock Ventures. ...